DYRK2 and prostate adenocarcinoma: Meanwhile, disease-free survival (DFS) data showed that high expression of DYRK2 suggested poor prognosis in TCGA cases in ACC (Adrenocortical carcinoma) (P = 0.025), KICH(Kidney Chromophobe) (P = 0.027) and PRAD (Prostate adenocarcinoma) (P = 0.015) (Fig. 2B).